MedPath

Tegafur

Generic Name
Tegafur
Brand Names
Teysuno
Drug Type
Small Molecule
Chemical Formula
C8H9FN2O3
CAS Number
17902-23-7
Unique Ingredient Identifier
1548R74NSZ

Overview

Tegafur (INN, BAN, USAN) is a prodrug of Fluorouracil (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers. It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with Gimeracil and Oteracil, or along with Fluorouracil as Tegafur-uracil. Tegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by ensuring high concentrations of 5-FU at a lower dose of tegafur . When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the World Health Organization's List of Essential Medicines.

Background

Tegafur (INN, BAN, USAN) is a prodrug of Fluorouracil (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers. It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with Gimeracil and Oteracil, or along with Fluorouracil as Tegafur-uracil. Tegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by ensuring high concentrations of 5-FU at a lower dose of tegafur . When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the World Health Organization's List of Essential Medicines.

Indication

Indicated for the treatment of cancer usually in combination with other biochemically modulating drugs. Indicated in adults for the treatment of advanced gastric cancer when given in combination with Cisplatin . Indicated for the first-line treatment of metastatic colorectal cancer with Uracil and calcium folinate .

Associated Conditions

  • Stage IV Gastric Cancer

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

UFT CAPSULE
Manufacturer:TAIHO PHARMACEUTICAL CO LTD
Form:CAPSULE
Strength:100 mg
Online:Yes
Approved: 1989/09/22
Approval:SIN03692P
TS-ONE Capsule 25
Manufacturer:Taiho Pharmaceutical Co., Ltd. (Tokushima Plant)
Form:CAPSULE
Strength:25mg
Online:Yes
Approved: 2009/07/13
Approval:SIN13673P
TS-ONE Capsule 20
Manufacturer:Taiho Pharmaceutical Co., Ltd. (Tokushima Plant)
Form:CAPSULE
Strength:20mg
Online:Yes
Approved: 2009/07/13
Approval:SIN13672P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath